History, biological mechanisms of action and clinical indications of intravenous immunoglobulin (IVIG) preparations

被引:0
|
作者
Teeling, JL [1 ]
Bleeker, WK [1 ]
Hack, CE [1 ]
机构
[1] CLB, Dept Immunolpathol, Amsterdam, Netherlands
关键词
Intravenous immunoglobulins; Fc receptors; IgG dimers; side effects;
D O I
暂无
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Intravenous immunoglobulin (IVIG) preparations were initially introduced as replacement therapy in primary antibody deficiency disorders and, as time passed by, have been found beneficial in patients with autoimmune disorders and systemic inflammatory disease as well. In spite of its widespread use, the precise mechanism of action of IVIG is still largely unknown. Different mechanisms have been proposed, such as Fcgamma receptor blockade, inhibition of complement deposition, neutralization of superantigens, neutralization of cytokines and manipulation of the idiotypic network. Although well tolerated by most patients, IVIG may induce side effects in some patients. The fact that most of the commercially available IVIG preparation are free of complement-activating activity suggests that other effector mechanisms are involved. In this review, different biological mechanisms of action of IVIG as well as the causes of side effects are discussed. (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:91 / 100
页数:10
相关论文
共 50 条
  • [1] Intravenous immunoglobulin - New indications and mechanisms of action
    Shoenfeld, Y
    Gershwin, ME
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2005, 29 (03) : 165 - 166
  • [2] Mechanisms of action of intravenous immunoglobulin (IVIg) in autoimmune and neuromuscular diseases
    Sharshar, T
    Kaveri, S
    Kazatchkine, M
    [J]. CLINICAL NEUROPHYSIOLOGY: FROM RECEPTORS TO PERCEPTION, 1999, 50 : 486 - 492
  • [3] Factor XI is a contaminant in intravenous immunoglobulin (IVIG) preparations
    Kon, RH
    Wolberg, AS
    Oliver, JA
    Monroe, DM
    Hoffman, M
    [J]. THROMBOSIS AND HAEMOSTASIS, 1999, : 459 - 460
  • [4] Antiphospholipid antibody levels in intravenous immunoglobulin (IVIg) preparations
    Sherer, Y
    Wu, R
    Krause, I
    Peter, JB
    Shoenfeld, Y
    [J]. LUPUS, 2001, 10 (08) : 568 - 570
  • [5] CHARACTERIZATION OF ANTICYTOKINE AUTOANTIBODIES IN INTRAVENOUS IMMUNOGLOBULIN (IVIG) PREPARATIONS
    Rosen, Lindsey B.
    Glowinski, Rebecca M.
    Berger, Melvin
    Browne, Sarah K.
    Holland, Steven M.
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (03) : 270 - 271
  • [6] APPARENT AUTOANTIBODY ACTIVITY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) PREPARATIONS
    PETER, JB
    BARKA, NE
    AGOPIAN, MS
    [J]. CLINICAL RESEARCH, 1991, 39 (02): : A436 - A436
  • [7] OPSONIC ACTIVITY OF COMMERCIALLY AVAILABLE INTRAVENOUS IMMUNOGLOBULIN (IVIG) PREPARATIONS
    WEISMAN, LE
    WILSON, SR
    STEVENS, S
    CRUESS, DF
    ANDERSEN, LA
    FISCHER, GW
    [J]. PEDIATRIC RESEARCH, 1994, 35 (04) : A306 - A306
  • [8] Coagulation factor XI is present in intravenous immunoglobulin (IVIG) preparations
    Hoffman, MR
    Kon, R
    Wolberg, A
    Monroe, DM
    [J]. TRANSFUSION, 1999, 39 (10) : 99S - 99S
  • [9] IVIG - Mechanisms of Action, Indications and new Guidelines
    Enk, A.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 61 - 61
  • [10] Intravenous immunoglobulin:: An update on the clinical use and mechanisms of action
    Negi, Vir-Singh
    Elluru, Sriramulu
    Siberil, Sophie
    Graff-Dubois, Stephanie
    Mouthon, Luc
    Kazatchkine, Michel D.
    Lacroix-Desmazes, Sebastien
    Bayry, Jagadeesh
    Kaveri, Srini V.
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2007, 27 (03) : 233 - 245